Top

Published in:

01-04-2014 | Research Article

Common genetic variants at 1q22 and 10q23 and gastric cancer susceptibility in a Korean population

Authors: Hye-Rim Song, Hee Nam Kim, Sun-Seog Kweon, Jin-Su Choi, Hyun Jeong Shim, Sang Hee Cho, Ik Joo Chung, Young-Kyu Park, Soo Hyun Kim, Yoo-Duk Choi, Kyung Woong Joo, Min-Ho Shin

Published in: Tumor Biology | Issue 4/2014

Abstract

Genetic variants at 1q22 and 10q23 were identified as genetic markers of both gastric cancer and esophageal squamous cell carcinoma susceptibility by two genome-wide association studies. The aim of this study was to determine whether rs4072037A > G in MUC1 at 1q22 and rs2274223A > G in PLCE1 at 10q23 are associated with a risk of gastric cancer in a Korean population. We conducted a large-scale case–control study of 3,245 patients with gastric cancer and 1,700 controls. The allele frequencies of rs4072037G and rs2274223G were 11.2 and 25.5 % among patients with gastric cancer, compared with 12.8 and 26.4 %, respectively, among controls. We found that the rs4072037 AG genotype was significantly associated with a reduced risk of gastric cancer [odds ratios (OR) = 0.78; 95 % confidence interval (CI) = 0.67–0.91 for AG vs AA]. Compared with the rs2274223 AA genotype, we found a significant association between the rs2274223 AG genotype and a weakly reduced risk of gastric cancer (OR = 0.87; 95 % CI = 0.76–0.99 for AG vs AA). Our data suggest that genetic variants at 1q22 and 10q23 play a role in gastric carcinogenesis.

Jung KW, Park S, Won YJ, Kong HJ, Lee JY, Seo HG, et al. Prediction of cancer incidence and mortality in Korea, 2012. Cancer Res Treat. 2012;44:25–31.PubMedCentralPubMedCrossRef

Crew KD, Neugut AI. Epidemiology of gastric cancer. World Journal of Gastroenterology: WJG. 2006;12:354–62.PubMed

Galvan A, Ioannidis JP, Dragani TA. Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer. Trends in Genetics: TIG. 2010;26:132–41.PubMedCentralPubMedCrossRef

Abnet CC, Freedman ND, Hu N, Wang Z, Yu K, Shu XO, et al. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet. 2010;42:764–7.PubMedCentralPubMedCrossRef

Wang LD, Zhou FY, Li XM, Sun LD, Song X, Jin Y, et al. Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet. 2010;42:759–63.PubMedCrossRef

Saeki N, Saito A, Choi IJ, Matsuo K, Ohnami S, Totsuka H, et al. A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer. Gastroenterology. 2011;140:892–902.PubMedCrossRef

Zhang H, Jin G, Li H, Ren C, Ding Y, Zhang Q, et al. Genetic variants at 1q22 and 10q23 reproducibly associated with gastric cancer susceptibility in a Chinese population. Carcinogenesis. 2011;32:848–52.PubMedCentralPubMedCrossRef

Wang M, Zhang R, He J, Qiu L, Li J, Wang Y, et al. Potentially functional variants of PLCE1 identified by GWASS contribute to gastric adenocarcinoma susceptibility in an eastern Chinese population. PloS One. 2012;7:e31932.PubMedCentralPubMedCrossRef

Yang XX, Li FX, Zhou CP, Hu NY, Wu YS, Li M. Association of genetic polymorphisms at 1q22 but not 10q23 with gastric cancer in a southern Chinese population. Asian Pacific Journal of Cancer Prevention: APJCP. 2012;13:2519–22.PubMedCrossRef

10.

Kim HN, Lee IK, Kim YK, Tran HT, Yang DH, Lee JJ, et al. Association between folate-metabolizing pathway polymorphism and non-Hodgkin lymphoma. Br J Haematol. 2008;140:287–94.PubMedCrossRef

11.

Jia Y, Persson C, Hou L, Zheng Z, Yeager M, Lissowska J, et al. A comprehensive analysis of common genetic variation in MUC1, MUC5AC, MUC6 genes and risk of stomach cancer. Cancer Causes & Control: CCC. 2010;21:313–21.PubMedCentralPubMedCrossRef

12.

Palmer AJ, Lochhead P, Hold GL, Rabkin CS, Chow WH, Lissowska J, et al. Genetic variation in C20orf54, PLCE1 and MUC1 and the risk of upper gastrointestinal cancers in Caucasian populations. Eur J Cancer Prev. 2012;21:541–4.PubMedCentralPubMedCrossRef

13.

Frank B, Weck MN, Muller H, Klopp N, Illig T, Raum E, et al. Polymorphisms in MUC1, MUC2, MUC5B and MUC6 genes are not associated with the risk of chronic atrophic gastritis. Eur J Cancer. 2012;48:114–20.PubMedCrossRef

14.

Zheng L, Zhu C, Gu J, Xi P, Du J, Jin G. Functional polymorphism rs4072037 in MUC1 gene contributes to the susceptibility to gastric cancer: evidence from pooled 6,580 cases and 10,324 controls. Mol Biol Rep. 2013;40:5791–6.PubMedCrossRef

15.

Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9:874–85.PubMedCentralPubMedCrossRef

16.

Ng W, Loh AX, Teixeira AS, Pereira SP, Swallow DM. Genetic regulation of MUC1 alternative splicing in human tissues. Br J Cancer. 2008;99:978–85.PubMedCentralPubMedCrossRef

17.

Gu H, Ding G, Zhang W, Liu C, Chen Y, Chen S, et al. Replication study of PLCE1 and C20orf54 polymorphism and risk of esophageal cancer in a Chinese population. Mol Biol Rep. 2012;39:9105–11.PubMedCrossRef

18.

Bye H, Prescott NJ, Lewis CM, Matejcic M, Moodley L, Robertson B, et al. Distinct genetic association at the PLCE1 locus with oesophageal squamous cell carcinoma in the South African population. Carcinogenesis. 2012;33:2155–61.PubMedCentralPubMedCrossRef

19.

Ma H, Wang LE, Liu Z, Sturgis EM, Wei Q. Association between novel PLCE1 variants identified in published esophageal cancer genome-wide association studies and risk of squamous cell carcinoma of the head and neck. BMC Cancer. 2011;11:258.PubMedCentralPubMedCrossRef

20.

Hao NB, He YF, Zhang D, Luo G, Chen BJ, Zhang Y, et al. PLCE1 polymorphism and upper gastrointestinal cancer risk: a meta-analysis. PloS One. 2013;8:e67229.PubMedCentralPubMedCrossRef

Title: Common genetic variants at 1q22 and 10q23 and gastric cancer susceptibility in a Korean population
Authors: Hye-Rim Song
Hee Nam Kim
Sun-Seog Kweon
Jin-Su Choi
Hyun Jeong Shim
Sang Hee Cho
Ik Joo Chung
Young-Kyu Park
Soo Hyun Kim
Yoo-Duk Choi
Kyung Woong Joo
Min-Ho Shin
Publication date: 01-04-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1409-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Anti-hepatoma cells function of luteolin through inducing apoptosis and cell cycle arrest

Transforming growth factor-beta1 signaling blockade attenuates gastric cancer cell-induced peritoneal mesothelial cell fibrosis and alleviates peritoneal dissemination both in vitro and in vivo

Association of the vascular endothelial growth factor (VEGF) gene single-nucleotide polymorphisms with osteosarcoma susceptibility in a Chinese population

Strong claudin 5 expression is a poor prognostic sign in pancreatic adenocarcinoma

Association between a functional insertion/deletion polymorphism in IL1A gene and risk of papillary thyroid carcinoma

Filamin A regulates MMP-9 expression and suppresses prostate cancer cell migration and invasion

Keynote webinar | Spotlight on antibody–drug conjugates in cancer